Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 .
Technical analysis indicates a recent "sell signal" from a pivot top point reached in late April 2026. Financial Health & Outlook mylan stock buy or sell
Recent FDA warnings and import alerts regarding manufacturing facilities in India (Indore and Nashik) continue to impact EBITDA estimates. Discounted Cash Flow (DCF) models suggest the stock
The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings. mylan stock buy or sell
Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion .